April 2026 clinical trial highlights
Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).
Each month, we'll highlight a few of the many trials enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with systemic sclerosis associated with ILD (SSc-ILD)
BLISSc-ILD
- Study ID: NCT05878717
- Trial Phase: Phase 2/3
- Intervention: Subcutaneous injection
- Sponsor: GlaxoSmithKline
- Study Contact: US GSK Clinical Trials Call Center (877.379.3718; GSKClinicalSupportHD@gsk.com)
Seeking participants with IPF
A Phase 2 Study of LTI-03 in Patients With IPF
- Study ID: NCT06968845
- Trial Phase: Phase 2
- Intervention: Inhaled drug
- Sponsor: Rein Therapeutics
- Study Contact: Steven A. Shoemaker, MD (720.560.2167; sshoemaker@nicosof.com); Shawna H. Evans (603.557.0005; sevans@reintx.com)
Seeking participants with IPF
WISPer
- Study ID: NCT06967805
- Trial Phase: Phase 2a
- Intervention: Intravenous injection
- Sponsor: Mediar Therapeutics
- Study Contact: WISPer@mediartx.com
Seeking participants with IPF
Zinc and Nicotinamide Riboside for IPF
- Study ID: NCT06567717
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: Cedars-Sinai Medical Center
- Study Contact: Study Coordinator (310.423.8474; GroupLungResearch@cshs.org); Tanzira Zaman, MD (Tanzira.Zaman@cshs.org)
Share your research study experience with us
We are interested in learning about your experience participating in research studies for ILD. If you would like to share your journey, please complete the "My research study story" online form. We will select story submissions to feature in the "Putting a face to the science" section of our clinical trials newsletter (see below). This initiative aims to highlight unique perspectives from the PF and ILD community.
Thank you for your consideration and taking the time to share your experience with the PFF and broader community. We sincerely appreciate your contribution to our future newsletters.
Putting a face to the science: living with SSc-ILD
Rodrigo's journey with SSc-ILD began suddenly when he experienced shortness of breath, which led to him being hospitalized. While in the hospital, a computed tomography (CT) scan confirmed his lung fibrosis. Months later, an endocrinologist linked the fibrosis to scleroderma. Rodrigo struggled to process this information.
In 2018, after recovering from pneumonia, he began using supplemental oxygen full time and eventually had to step away from his career as a paramedic, a role that had been a central part of his identity. Despite these challenges, Rodrigo found support and resources that helped him move forward.
Pulmonary rehabilitation led him to the PFF, where he found educational materials and support groups. Rodrigo’s doctors also referred him to a clinical trial, where he participated in monthly study visits for blood work and spirometry, which he credits as a great experience overall. After receiving a lung transplant in 2020, Rodrigo became a PFF Ambassador, sharing his story to support others facing similar challenges. With the support of his wife and family, and a positive outlook, Rodrigo continues to live life fully.
For an overview of SSc-ILD, visit the Scleroderma-Associated Interstitial Lung Disease Fact Sheet.
 |
Updates from end-of-phase 2 meeting with the FDA
In March 2026, Trevi Therapeutics announced the outcome of its end-of-phase 2 meeting with the Food and Drug Administration (FDA) regarding nalbuphine ER (Haduvio™).
An end-of-phase 2 meeting provides pharmaceutical teams the opportunity to meet with the FDA to discuss plans for phase 3 studies. In this meeting teams typically review study design, protocols, and safety data. These important discussions help ensure the drug development team’s plans align with elements the FDA will want to consider in the drug approval process.
The end-of-phase 2 meeting provided Trevi with valuable feedback from the FDA regarding their development plan for nalbuphine ER in treating chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough (RCC). With the FDA’s feedback, Trevi will move forward with two pivotal phase 3 trials.
Trevi plans to initiate the first phase 3 trial in the second quarter of 2026 and the second phase 3 trial in the second half of 2026. The studies will examine the effect of the medication on how frequently a participant coughs measured by a cough monitor.
Currently, there are no approved therapies for chronic cough among patients with IPF. These clinical trial updates are important steps forward for people living with IPF and their unmet needs in relation to cough.
Positive results from a phase 3 IPF study
In March 2026, United Therapeutics announced its phase 3 TETON-1 study met its primary endpoint, which evaluated the use of the treprostinil (Tyvaso®) in IPF. A primary endpoint is a key measurement researchers use to determine the efficacy of a medication or intervention. The study demonstrated that individuals with IPF who took treprostinil experienced better preservation of lung function, reduced disease worsening, and reduced acute IPF exacerbations.
These findings are particularly noteworthy as treprostinil acts on several different pathways within the lungs. This further highlights treprostinil’s potential to reverse disease across multiple measures, representing a significant advancement for the IPF community.
Treprostinil is currently used to treat other disease processes including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The TETON-1 study did not identify any new safety concerns with treprostinil that had not been identified in previous treprostinil studies. United Therapeutics plans to submit an application to the FDA to add IPF as an approved disease that treprostinil can treat.
If you have any questions or comments about this newsletter, please email partnerships@